West Pharmaceutical tops Q3 net sales, profit expectations, raises FY guidance
WST•West Pharmaceutical’s Q3 net sales rose 8.7% to $874.50 million and adjusted EPS increased 35.7% to $2.66, beating analyst expectations. The company raised its 2026 net sales guidance to $3.41 billion-$3.42 billion and adjusted diluted EPS forecast to $9.38-$9.48.
1. Quarterly results
West Pharmaceutical reported Q3 net sales of $874.50 million, above the $825.70 million analyst consensus, and adjusted EPS of $2.66, above the $2.19 consensus. Net sales rose 8.7%, while adjusted EPS increased 35.7%.
2. Raised 2026 outlook
The company lifted its 2026 net sales guidance to $3.41 billion-$3.42 billion and its adjusted diluted EPS forecast to $9.38-$9.48. It now expects organic net sales growth of 11.3%-11.6%.
3. Sales and repurchases
West Pharmaceutical said growth was led by its High-Value Product Components business and that its Proprietary Products segment drove net sales growth. The company repurchased $231 million of stock in Q3.
